A citation-based method for searching scientific literature

Federico Cappuzzo, Antonio Marchetti, Margaret Skokan, Elisa Rossi, Sujatha Gajapathy, Lara Felicioni, Maela Del Grammastro, Maria Grazia Sciarrotta, Fiamma Buttitta, Matteo Incarbone, Luca Toschi, Giovanna Finocchiaro, Annarita Destro, Luigi Terracciano, Massimo Roncalli, Marco Alloisio, Armando Santoro, Marileila Varella-Garcia. J Clin Oncol 2009
Times Cited: 422







List of co-cited articles
841 articles co-cited >1



Times Cited
  Times     Co-cited
Similarity


MET Amplification and Exon 14 Splice Site Mutation Define Unique Molecular Subgroups of Non-Small Cell Lung Carcinoma with Poor Prognosis.
Joanna H Tong, Sai F Yeung, Anthony W H Chan, Lau Y Chung, Shuk L Chau, Raymond Wai Ming Lung, Carol Y Tong, Chit Chow, Edith K Y Tin, Yau H Yu,[...]. Clin Cancer Res 2016
194
36

Activation of MET via diverse exon 14 splicing alterations occurs in multiple tumor types and confers clinical sensitivity to MET inhibitors.
Garrett M Frampton, Siraj M Ali, Mark Rosenzweig, Juliann Chmielecki, Xinyuan Lu, Todd M Bauer, Mikhail Akimov, Jose A Bufill, Carrie Lee, David Jentz,[...]. Cancer Discov 2015
393
34

MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling.
Jeffrey A Engelman, Kreshnik Zejnullahu, Tetsuya Mitsudomi, Youngchul Song, Courtney Hyland, Joon Oh Park, Neal Lindeman, Christopher-Michael Gale, Xiaojun Zhao, James Christensen,[...]. Science 2007
34

Response to MET inhibitors in patients with stage IV lung adenocarcinomas harboring MET mutations causing exon 14 skipping.
Paul K Paik, Alexander Drilon, Pang-Dian Fan, Helena Yu, Natasha Rekhtman, Michelle S Ginsberg, Laetitia Borsu, Nikolaus Schultz, Michael F Berger, Charles M Rudin,[...]. Cancer Discov 2015
363
33

MET Exon 14 Mutations in Non-Small-Cell Lung Cancer Are Associated With Advanced Age and Stage-Dependent MET Genomic Amplification and c-Met Overexpression.
Mark M Awad, Geoffrey R Oxnard, David M Jackman, Daniel O Savukoski, Dimity Hall, Priyanka Shivdasani, Jennifer C Heng, Suzanne E Dahlberg, Pasi A Jänne, Suman Verma,[...]. J Clin Oncol 2016
309
32

MET amplification occurs with or without T790M mutations in EGFR mutant lung tumors with acquired resistance to gefitinib or erlotinib.
James Bean, Cameron Brennan, Jin-Yuan Shih, Gregory Riely, Agnes Viale, Lu Wang, Dhananjay Chitale, Noriko Motoi, Janos Szoke, Stephen Broderick,[...]. Proc Natl Acad Sci U S A 2007
29

Targeting MET in Lung Cancer: Will Expectations Finally Be MET?
Alexander Drilon, Federico Cappuzzo, Sai-Hong Ignatius Ou, D Ross Camidge. J Thorac Oncol 2017
160
25

Characterization of 298 Patients with Lung Cancer Harboring MET Exon 14 Skipping Alterations.
Alexa B Schrock, Garrett M Frampton, James Suh, Zachary R Chalmers, Mark Rosenzweig, Rachel L Erlich, Balazs Halmos, Jonathan Goldman, Patrick Forde, Kurt Leuenberger,[...]. J Thorac Oncol 2016
158
24

Met, metastasis, motility and more.
Carmen Birchmeier, Walter Birchmeier, Ermanno Gherardi, George F Vande Woude. Nat Rev Mol Cell Biol 2003
24

Results From the Phase III Randomized Trial of Onartuzumab Plus Erlotinib Versus Erlotinib in Previously Treated Stage IIIB or IV Non-Small-Cell Lung Cancer: METLung.
David R Spigel, Martin J Edelman, Kenneth O'Byrne, Luis Paz-Ares, Simonetta Mocci, See Phan, David S Shames, Dustin Smith, Wei Yu, Virginia E Paton,[...]. J Clin Oncol 2017
149
23


Met gene copy number predicts the prognosis for completely resected non-small cell lung cancer.
Katsuhiro Okuda, Hidefumi Sasaki, Haruhiro Yukiue, Motoki Yano, Yoshitaka Fujii. Cancer Sci 2008
152
21

Phase Ib/II Study of Capmatinib (INC280) Plus Gefitinib After Failure of Epidermal Growth Factor Receptor (EGFR) Inhibitor Therapy in Patients With EGFR-Mutated, MET Factor-Dysregulated Non-Small-Cell Lung Cancer.
Yi-Long Wu, Li Zhang, Dong-Wan Kim, Xiaoqing Liu, Dae Ho Lee, James Chih-Hsin Yang, Myung-Ju Ahn, Johan F Vansteenkiste, Wu-Chou Su, Enriqueta Felip,[...]. J Clin Oncol 2018
111
20

Somatic mutations lead to an oncogenic deletion of met in lung cancer.
Monica Kong-Beltran, Somasekar Seshagiri, Jiping Zha, Wenjing Zhu, Kaumudi Bhawe, Nerissa Mendoza, Thomas Holcomb, Kanan Pujara, Jeremy Stinson, Ling Fu,[...]. Cancer Res 2006
324
19

Identifying the Appropriate FISH Criteria for Defining MET Copy Number-Driven Lung Adenocarcinoma through Oncogene Overlap Analysis.
Sinéad A Noonan, Lynne Berry, Xian Lu, Dexiang Gao, Anna E Barón, Patrick Chesnut, Jamie Sheren, Dara L Aisner, Dan Merrick, Robert C Doebele,[...]. J Thorac Oncol 2016
79
24

Randomized phase II trial of Onartuzumab in combination with erlotinib in patients with advanced non-small-cell lung cancer.
David R Spigel, Thomas J Ervin, Rodryg A Ramlau, Davey B Daniel, Jerome H Goldschmidt, George R Blumenschein, Maciej J Krzakowski, Gilles Robinet, Benoit Godbert, Fabrice Barlesi,[...]. J Clin Oncol 2013
353
17

An overview of the c-MET signaling pathway.
Shawna Leslie Organ, Ming-Sound Tsao. Ther Adv Med Oncol 2011
390
17

High MET gene copy number leads to shorter survival in patients with non-small cell lung cancer.
Heounjeong Go, Yoon Kyung Jeon, Hyo Jin Park, Sook-Whan Sung, Jeong-Wook Seo, Doo Hyun Chung. J Thorac Oncol 2010
150
17

Genotypic and histological evolution of lung cancers acquiring resistance to EGFR inhibitors.
Lecia V Sequist, Belinda A Waltman, Dora Dias-Santagata, Subba Digumarthy, Alexa B Turke, Panos Fidias, Kristin Bergethon, Alice T Shaw, Scott Gettinger, Arjola K Cosper,[...]. Sci Transl Med 2011
17

Next-Generation Sequencing of Pulmonary Sarcomatoid Carcinoma Reveals High Frequency of Actionable MET Gene Mutations.
Xuewen Liu, Yuxia Jia, Mark B Stoopler, Yufeng Shen, Haiying Cheng, Jinli Chen, Mahesh Mansukhani, Sanjay Koul, Balazs Halmos, Alain C Borczuk. J Clin Oncol 2016
190
16

Functional expression and mutations of c-Met and its therapeutic inhibition with SU11274 and small interfering RNA in non-small cell lung cancer.
Patrick C Ma, Ramasamy Jagadeeswaran, Simha Jagadeesh, Maria S Tretiakova, Vidya Nallasura, Edward A Fox, Mark Hansen, Erik Schaefer, Katsuhiko Naoki, Alan Lader,[...]. Cancer Res 2005
440
16

Activation of MET by gene amplification or by splice mutations deleting the juxtamembrane domain in primary resected lung cancers.
Ryoichi Onozato, Takayuki Kosaka, Hiroyuki Kuwano, Yoshitaka Sekido, Yasushi Yatabe, Tetsuya Mitsudomi. J Thorac Oncol 2009
207
16

Analysis of tumor specimens at the time of acquired resistance to EGFR-TKI therapy in 155 patients with EGFR-mutant lung cancers.
Helena A Yu, Maria E Arcila, Natasha Rekhtman, Camelia S Sima, Maureen F Zakowski, William Pao, Mark G Kris, Vincent A Miller, Marc Ladanyi, Gregory J Riely. Clin Cancer Res 2013
15

Osimertinib in Untreated EGFR-Mutated Advanced Non-Small-Cell Lung Cancer.
Jean-Charles Soria, Yuichiro Ohe, Johan Vansteenkiste, Thanyanan Reungwetwattana, Busyamas Chewaskulyong, Ki Hyeong Lee, Arunee Dechaphunkul, Fumio Imamura, Naoyuki Nogami, Takayasu Kurata,[...]. N Engl J Med 2018
15

Targeting MET in cancer: rationale and progress.
Ermanno Gherardi, Walter Birchmeier, Carmen Birchmeier, George Vande Woude. Nat Rev Cancer 2012
986
14

A novel kinase inhibitor, INCB28060, blocks c-MET-dependent signaling, neoplastic activities, and cross-talk with EGFR and HER-3.
Xiangdong Liu, Qian Wang, Gengjie Yang, Cindy Marando, Holly K Koblish, Leslie M Hall, Jordan S Fridman, Elham Behshad, Richard Wynn, Yu Li,[...]. Clin Cancer Res 2011
138
14

Targeting MET Amplification as a New Oncogenic Driver.
Hisato Kawakami, Isamu Okamoto, Wataru Okamoto, Junko Tanizaki, Kazuhiko Nakagawa, Kazuto Nishio. Cancers (Basel) 2014
65
21

MET amplification status in therapy-naïve adeno- and squamous cell carcinomas of the lung.
Hans-Ulrich Schildhaus, Anne M Schultheis, Josef Rüschoff, Elke Binot, Sabine Merkelbach-Bruse, Jana Fassunke, Wolfgang Schulte, Yon-Dschun Ko, Andreas Schlesinger, Marc Bos,[...]. Clin Cancer Res 2015
97
14

Antitumor activity of crizotinib in lung cancers harboring a MET exon 14 alteration.
Alexander Drilon, Jeffrey W Clark, Jared Weiss, Sai-Hong Ignatius Ou, D Ross Camidge, Benjamin J Solomon, Gregory A Otterson, Liza C Villaruz, Gregory J Riely, Rebecca S Heist,[...]. Nat Med 2020
96
14

Identification of the hepatocyte growth factor receptor as the c-met proto-oncogene product.
D P Bottaro, J S Rubin, D L Faletto, A M Chan, T E Kmiecik, G F Vande Woude, S A Aaronson. Science 1991
13

Crizotinib in ROS1-rearranged non-small-cell lung cancer.
Alice T Shaw, Sai-Hong I Ou, Yung-Jue Bang, D Ross Camidge, Benjamin J Solomon, Ravi Salgia, Gregory J Riely, Marileila Varella-Garcia, Geoffrey I Shapiro, Daniel B Costa,[...]. N Engl J Med 2014
13

Activity of crizotinib (PF02341066), a dual mesenchymal-epithelial transition (MET) and anaplastic lymphoma kinase (ALK) inhibitor, in a non-small cell lung cancer patient with de novo MET amplification.
Sai-Hong Ignatius Ou, Eunice L Kwak, Christina Siwak-Tapp, Joni Dy, Kristin Bergethon, Jeffrey W Clark, D Ross Camidge, Benjamin J Solomon, Robert G Maki, Yung-Jue Bang,[...]. J Thorac Oncol 2011
319
13

High MET copy number and MET overexpression: poor outcome in non-small cell lung cancer patients.
Sanghui Park, Yoon-La Choi, Chang Ok Sung, Jungsuk An, Jinwon Seo, Myung-Ju Ahn, Jin Seok Ahn, Keunchil Park, Young Kee Shin, Ozgur Cem Erkin,[...]. Histol Histopathol 2012
114
12

MET as a possible target for non-small-cell lung cancer.
Ahad A Sadiq, Ravi Salgia. J Clin Oncol 2013
136
12


MET gene copy number predicts worse overall survival in patients with non-small cell lung cancer (NSCLC); a systematic review and meta-analysis.
Anastasios Dimou, Lemuel Non, Young Kwang Chae, William J Tester, Konstantinos N Syrigos. PLoS One 2014
42
28

c-MET mutational analysis in small cell lung cancer: novel juxtamembrane domain mutations regulating cytoskeletal functions.
Patrick C Ma, Takashi Kijima, Gautam Maulik, Edward A Fox, Martin Sattler, James D Griffin, Bruce E Johnson, Ravi Salgia. Cancer Res 2003
366
11

Molecular cloning of a new transforming gene from a chemically transformed human cell line.
C S Cooper, M Park, D G Blair, M A Tainsky, K Huebner, C M Croce, G F Vande Woude. Nature 1984
852
11

An orally available small-molecule inhibitor of c-Met, PF-2341066, exhibits cytoreductive antitumor efficacy through antiproliferative and antiangiogenic mechanisms.
Helen Y Zou, Qiuhua Li, Joseph H Lee, Maria E Arango, Scott R McDonnell, Shinji Yamazaki, Tatiana B Koudriakova, Gordon Alton, Jingrong J Cui, Pei-Pei Kung,[...]. Cancer Res 2007
537
11

Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma.
Tony S Mok, Yi-Long Wu, Sumitra Thongprasert, Chih-Hsin Yang, Da-Tong Chu, Nagahiro Saijo, Patrapim Sunpaweravong, Baohui Han, Benjamin Margono, Yukito Ichinose,[...]. N Engl J Med 2009
11

c-MET/phospho-MET protein expression and MET gene copy number in non-small cell lung carcinomas.
Koji Tsuta, Yoshiki Kozu, Takahiro Mimae, Akihiko Yoshida, Takashi Kohno, Ikuo Sekine, Tomohide Tamura, Hisao Asamura, Koh Furuta, Hitoshi Tsuda. J Thorac Oncol 2012
111
11


Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib.
Thomas J Lynch, Daphne W Bell, Raffaella Sordella, Sarada Gurubhagavatula, Ross A Okimoto, Brian W Brannigan, Patricia L Harris, Sara M Haserlat, Jeffrey G Supko, Frank G Haluska,[...]. N Engl J Med 2004
10

Phase III Multinational, Randomized, Double-Blind, Placebo-Controlled Study of Tivantinib (ARQ 197) Plus Erlotinib Versus Erlotinib Alone in Previously Treated Patients With Locally Advanced or Metastatic Nonsquamous Non-Small-Cell Lung Cancer.
Giorgio Scagliotti, Joachim von Pawel, Silvia Novello, Rodryg Ramlau, Adolfo Favaretto, Fabrice Barlesi, Wallace Akerley, Sergey Orlov, Armando Santoro, David Spigel,[...]. J Clin Oncol 2015
186
10

Cabozantinib in patients with advanced RET-rearranged non-small-cell lung cancer: an open-label, single-centre, phase 2, single-arm trial.
Alexander Drilon, Natasha Rekhtman, Maria Arcila, Lu Wang, Andy Ni, Melanie Albano, Martine Van Voorthuysen, Romel Somwar, Roger S Smith, Joseph Montecalvo,[...]. Lancet Oncol 2016
232
10

Improved diagnostics targeting c-MET in non-small cell lung cancer: expression, amplification and activation?
I Watermann, B Schmitt, F Stellmacher, J Müller, R Gaber, Ch Kugler, N Reinmuth, R M Huber, M Thomas, P Zabel,[...]. Diagn Pathol 2015
48
20

Alectinib versus Crizotinib in Untreated ALK-Positive Non-Small-Cell Lung Cancer.
Solange Peters, D Ross Camidge, Alice T Shaw, Shirish Gadgeel, Jin S Ahn, Dong-Wan Kim, Sai-Hong I Ou, Maurice Pérol, Rafal Dziadziuszko, Rafael Rosell,[...]. N Engl J Med 2017
948
10

PD-L1 expression, tumor mutational burden, and response to immunotherapy in patients with MET exon 14 altered lung cancers.
J K Sabari, G C Leonardi, C A Shu, R Umeton, J Montecalvo, A Ni, R Chen, J Dienstag, C Mrad, I Bergagnini,[...]. Ann Oncol 2018
104
10

Emerging molecular targets in oncology: clinical potential of MET/hepatocyte growth-factor inhibitors.
Elizabeth C Smyth, Francesco Sclafani, David Cunningham. Onco Targets Ther 2014
76
11

Germline and somatic mutations in the tyrosine kinase domain of the MET proto-oncogene in papillary renal carcinomas.
L Schmidt, F M Duh, F Chen, T Kishida, G Glenn, P Choyke, S W Scherer, Z Zhuang, I Lubensky, M Dean,[...]. Nat Genet 1997
9


Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.